Are there data to support full-dose anticoagulation added to an antiplatelet in recurrent peripheral arterial thrombosis requiring revascularization and stenting? 

This question comes up frequently at our institution. I previously consulted with our vascular surgery team who referred me to this trial of Edoxaban with SAPT, trying to avert what may be limb loss if the bypass graft/stent fails. We've often promoted rivaroxaban 2.5 mg po BID per VOYAGER PAD if we...

I am not aware of any data for full dose anticoagulation, only lower dose anticoagulation which was the subject of the VOYAGER PAD study that did show reduced MALE rates when low dose Xarelto was added to either ASA or Plavix.

Add the COMPASS Trial to the evidence in support of combined therapy, with an acceptable risk of bleeding.